Aptorum jumps on FDA orphan drug tag for cancer treatment

Aptorum

20/01/2022 14:02

** Biopharma co's  APM.O  shares rise as much as 35.2% to
$1.65 premarket 
    ** Stock set to snap seven-day losing streak if gains hold 
    ** Co says U.S. health regulator granted orphan drug
designation to its repurposed drug SACT-1  urn:newsml:reuters.com:*:nBw6CFmbVa 
    ** SACT-1, an orally administered drug, is a potential
treatment for patients with a type of rare childhood cancer
called neuroblastoma 
    ** Co plans to file an application with the FDA to commence
human trials for SACT-1 in 2022 
    ** Stock fell ~39% in 2021 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))